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Robert William Button  
‘Characterising Futile Autophagosome Synthesis Based Toxicity and 
its Implications in Disease’ 
Abstract 
Macroautophagy (‘autophagy’ hereafter) mediates the capture of aberrant 
cytoplasmic material into vesicles called autophagosomes, which then 
shuttle to lysosomes for degradation. Autophagy is implicated in 
numerous diseases, largely in a pro-survival role. However, autophagy 
has also been suggested as a form of programmed cell death (PCD), from 
cases of dying cells showing autophagosome accumulations. Debate 
occurs between whether these vesicles drive the lethality, or are instead a 
failing rescue attempt. This study aimed to provide clarity on this issue. 
Via the use of chemical and genetic strategies of inducing 
autophagosome accumulations, we found combining stimulators of 
autophagosome biogenesis with lysosomal degradation inhibitors gave 
rise to toxicity. Notably, this effect was dependent on the autophagy 
machinery and independent of other PCD routes. Research into the 
underlying mechanisms revealed an energy deficit under these conditions. 
Since autophagosomes cannot be recycled at lysosomes here, their 
continued synthesis affords no survival benefits, and instead just serves 
to deplete cellular energy further. For this reason, we designate this event 
‘Futile Autophagosome Synthesis’ (FAS) toxicity. Other contributors to 
this toxicity include the persistence of harmful agents like Reactive 
Oxygen Species (ROS). Having established our FAS model, we explored 
its relevance in both cancer and neurodegeneration. Importantly, we 
found FAS inducing strategies to be effective in tumour treatment. Also, 
inhibiting FAS reduced the toxicity seen in neurodegenerative disease. 
Therefore, not only does this study improve our knowledge of autophagy 
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1.1: An Overview of Autophagy 
Much like with our own refuse we generate as a society, the clearance and 
recycling of waste and faulty material is a challenge that all cells face. Fulfilling 
this goal is vital:  recycled material can provide a source for new products for 
the cell’s continued growth and survival; while at the same time clearance of 
potentially hazardous structures or species can prevent life-threatening cellular 
toxicity. To tackle this function multiple clearance systems have evolved in the 
cell, with the two major mechanisms being the ubiquitin-proteasome system 
(UPS), and the ‘self-eating’ process of autophagy [1].  
In the UPS, substrate proteins are labelled with chains of the ubiquitin protein, 
with these modifications allowing for their linkage to the 26S proteasome, 
whereupon they are degraded. This is achieved through a sequential series of 
enzymes- E1 (ubiquitin activating), E2 (ubiquitin conjugating), and E3 (ubiquitin 
ligating) [2, 3]. 
As the narrow entrance of the proteasome imposes a size limit on what 
substrates can be degraded, an alternative mechanism for the degradation of 
bulkier material, such as large protein aggregates and faulty organelles, is 
required [4]. This function is fulfilled by the process of autophagy, which broadly 
speaking, involves the capture of portions of cytoplasm, which are then 
delivered to lysosomes for degradation [5]. More specifically, this process 
encompasses three distinct pathways: microautophagy, chaperone-mediated 
autophagy, and macroautophagy. In microautophagy, the outer membrane of 
the lysosome itself forms tubules to directly engulf parts of the cytoplasm for 
degradation. Most of our knowledge of this phenomenon has come from yeast 
studies, with very limited support in mammals [6]. Chaperone-mediated 
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autophagy concerns the transport of cytoplasmic substrates across the 
lysosomal membrane. This interaction is mediated via transporters that 
recognise a specific motif expressed by certain substrates, and appears to 
chiefly function as a stress response [7-9]. The final process, macroautophagy, 
is by far the most well-studied of the three, and will be the focus of this report. 
For that reason, we shall refer to it henceforth simply as ‘autophagy’. Here, 
portions of cytoplasm are targeted and encapsulated within double-membraned 
vesicles called autophagosomes. These autophagosomes then traffic to the 
lysosomes, whereupon they fuse, forming an autolysosome [5, 10]. Lysosomal 
enzymes proceed to degrade the inner membrane of the autophagosome as 
well as its contents. The resulting material is released to the cytoplasm, where it 
can be recycled to form fresh amino acids for future protein synthesis [11] 
(summarised in Fig 1). 
Although first described in 1963, interest in autophagy has only really picked up 
in the last decade or so, with the field facing something of an explosion of late 
[12, 13]. This has been the result of a combination of advances in our 
knowledge of the machinery regulating the process, which in turn has led into 
an appreciation of the roles autophagy can play in numerous diseases. 
 Autophagy is truly an ancient process; it occurs in yeast right through to 
mammals, operating with a remarkably conserved set of regulators. It was 
originally identified as a starvation response, with cytoplasmic material captured 
and recycled as an emergency energy supply [14, 15]. However, befitting such 
a fundamental phenomenon, autophagy has since been implicated in a wealth 
of other diseases. Most of these roles seem to stem from autophagy’s functions 
in intracellular quality control [16]; with evidence for autophagy being protective 
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and preventative from tumour onset [17], neurodegeneration [18] and pathogen 
infection [19] amongst others. 
Despite these numerous pro-survival roles, autophagy has also been implicated 
as a mechanism of programmed cell death (PCD) [20-22]. This concept has 
arisen from the observation that dying cells can sometimes contain numerous 
autophagosomes, which have been suggested to inflict toxicity [23, 24]. 
However, this has been highly controversial, with critics drawing caveats at both 
this contrast with autophagy’s usual pro-survival functions, as well as a lack of 












Figure 1: An overview of macroautophagy 
The process of macroautophagy (referred to here as simply ‘autophagy’) involves the 
nucleation and elongation of a membrane to a vesicle called an autophagosome. 
Cytoplasmic portions are captured and engulfed in the process. Autophagosomes then 
shuttle to lysosomes, whereupon the two vesicles fuse, generating an autolysosome. The 
enzymes within the lysosome then degrade the autophagosome and its content, releasing 
the material to be recycled to fresh amino acids. The successful overall flow of the process 
is referred to as the ‘autophagy flux’. The pro-survival benefits of autophagy are two-fold: 
firstly, it represents  an energy supply during times of nutrient deprival, Second, the 
captured material can include waste proteins, toxins, and faulty organelles, thus meaning 
autophagy also provides an intracellular clean-up service. 
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To try and resolve this issue, this study aims to further explore and identify 
contexts whereby autophagy can exert cell death. Before describing the specific 
aims of this work more closely, details on the regulation of autophagy and key 
components of its machinery will be discussed. Following from this, the various 
roles autophagy reputedly plays in health and disease will be addressed, with 
specific focus on cancer and neurodegeneration, and finally the field of PCD will 
be covered, and where autophagy could potentially fit within it. 
1.2: History of autophagy research 
The field of autophagy research was born in 1963, when C de Duve first coined 
the phrase to describe the appearance of certain cytoplasmic vesicles in rat 
liver samples [12]. Although the available laboratory techniques were limited at 
this time, several important observations were made in these early years that 
helped shaped our awareness of the role of autophagy. The initial experiments 
identified double-membraned vesicles -autophagosomes- which contained 
portions of cytoplasm. It was also apparent these autophagosomes were related 
to the degradative lysosome. Interestingly, subjecting cells to starvation proved 
to be a stimulator of autophagy [12]. Follow-up experiments with hormones 
drew similar results; glucagon was found to promote the process, and 
conversely, insulin repressed it [28]. Amino acid levels were implicated as 
regulators of the process, with autophagy being employed by cells during 
sparse periods, and then repressed during times of plenty [29]. Therefore, it 
was clear that autophagy was a cellular response to starvation, allowing the cell 
to cannibalise non-vital components as an energy source during emergency 
[30]. Other work reported the appearance of some organelles engulfed within 
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autophagosomes, suggesting autophagy to also provide a form of quality 
control and waste removal process for cells [31, 32].  
Unfortunately, the technique base available was severely limited for the first few 
decades of autophagy work. Most major findings were from electron microscopy 
(EM) imaging, which came with caveats for analysing autophagy. As the 
process from autophagosome formation and cargo capture through to 
lysosomal fusion and degradation is quick and dynamic, it was hard to ascertain 
what stage was being observed when imaging. Also, whilst measurements of 
amino acid release are indeed influenced by autophagy activity, there are also 
numerous other factors that could affect them, leading to the risk of false 
positives and artefacts [33]. Although early drug work had given some indication 
to some autophagy mediators [34, 35], essentially the biggest barrier facing 
further development of the field was a lack of awareness of the genetic 
regulation of the process, with EM analysis only giving morphological output. 
Yeast- the source of our autophagy knowledge 
The aforementioned technical limitations facing autophagy research lingered for 
some thirty years after the initial founding of the field. However, this all changed 
when experiments in the Ohsumi lab using yeast (Saccharomyces cerevisiae) 
shed light on some of the main machinery for autophagosome formation [36]. 
The only observable organelle within yeast by phase-contrast microscopy is the 
vacuole, which shares some similar roles to the degradative lysosomes in other 
eukaryotic cells. Groups studying this organism observed that during periods of 
starvation, the formation of smaller vesicles around the vacuole occurs [37-39]. 
Closer EM analysis confirmed these vesicles to be autophagosomes, with the 
membrane fusion dynamics between autophagosome and vacuole bearing 
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similarity with that already seen for autophagosome and lysosome in 
mammalian cells [40]. With this consistency, Ohsumi and colleagues performed 
a large-scale genetic mutant screen, and through the simple use of light 
microscopy, selected for colonies that were defective for autophagosome 
formation. Defective colonies were assessed under multiple conditions, 
comprising: autophagosome numbers during starvation of carbon, nitrogen or 
single amino acids (autophagosome stimulatory conditions in healthy cells); 
bulk protein degradation (a reduction to degradation would suggest a loss of 
autophagosome formation); and viability with nitrogen starvation (autophagy is 
required to promote survival during starvation). From this analysis came the 
identification of the first of the family of AuTophaGy-related (Atg) genes, dubbed 
Atg1. Subsequent screens isolated another 14 Atg genes (Atg2-15) [36]. At 
around the same time, another group were making similar discoveries, with 
these publications paving the way for all future autophagy research [41]. Over 
the next 10 years came more understanding of the reactions and processes that 
are involved in autophagosome synthesis and maturation (which will be 
discussed in more detail in the next section).  
Following their identification in Yeast, efforts turned to exploring if the same 
machinery for autophagy was conserved in higher eukaryotes. Importantly, the 
Atg family is highly conserved across phyla; with most of the genes having 
homologues right the way through to mammals [17, 42-47]. To date, around 40 
members of the Atg family have now been identified [48]. The aforementioned 
works have paved the way for the explosion in autophagy research that has 
occurred in the past decade or so, with the process being implicated in an 
incredibly diverse range of roles and diseases [13]. 
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1.3: The machinery & manipulation of autophagy 
From the pioneering work of Ohsumi and colleagues, our knowledge and 
appreciation of the numerous factors and effectors involved across the whole 
process of autophagy has rapidly expanded [36]. This has been aided by the 
great degree of conservation seen in the autophagy machinery across 
organisms, with homologues of mediators first identified in yeast seen right up 
to mammals [42]. This understanding has allowed for the development of 
autophagy manipulation strategies, revolutionising our view of the functional 
roles of autophagy as well as potential scope for its therapeutic application. This 
section will provide an overview of the current perspective of the mechanisms 
and mediators at play throughout the whole process of autophagy: from origins 
of the autophagophore and the initiating signals, on to the completion of the 
autophagosome, and finally its meeting with and degradation at the lysosome 
(summarised in Fig 2).   
Autophagosome Membrane Origin 
Despite the rapid developments in our understanding of the machinery of 
autophagosome formation, the origins of the initial autophagophore membrane 
have proven an area of uncertainty and contention [49]. In yeast, 
autophagosomes have been shown to form at the pre-autophagosome structure 
(PAS), which is located in the proximity of the vacuole. Here, the various 
components necessary for autophagosome completion can accumulate to carry 
out the formation process [50]. However, such a region has proven more 
difficult to find in mammalian cells. Generally, two main theories have been 
proposed: 1) Autophagosomes are synthesised de novo from available 





















and/or provide a suitable site for autophagosome formation [50, 51]. The former 
concept has largely lost support in favour of the latter, in light of a number of 
Figure 2: Mammalian autophagosome synthesis 
The formation of autophagosomes in mammals proceeds through a sequential activation 
cascade of a series of complexes. One of the main regulators of this process is the cell 
growth and proliferation mediator mTOR. Under normal conditions mTOR represses 
autophagy by binding the ULK complex with the aid of effectors like Raptor. However, upon 
the onset of cellular stress (such as starvation) mTOR signalling is blocked (in this example 
by the nutrient sensing AMPK), and autophagosome formation can proceed. The first 
complex, ULK, activates the Beclin1/PI3K complex. At the core of this complex is Vps34, 
which generates PI(3)P and leads to nucleation of the membrane to the crescent shaped 
autophagophore. PI(3)P recruits effectors required for the elongation of autophagophore. 
Membrane elongation is chiefly mediated by two ubiquitin-like (UBL) conjugations; ATG5-
12, and LC3-PE. In the first, ATG12 is conjugated to ATG5 via processing by ATG7 
(serving as an E1-like enzyme) and ATG10 (E2-like), before binding non-covalently to 
ATG16. In the second, LC3 is cleaved by ATG4, then conjugated to PE through ATG7 (E1-
like) and ATGG3 (E2-like), and finally ATG12-5-16 (E3-like). Successful elongation results 
in the formation of the double-membraned autophagosome. 
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recent studies. The most strongly implicated organelle in the origins of the 
autophagosome is the endoplasmic reticulum (ER) [52]. Both 2D EM and 3D 
EM tomography have revealed contact between the ER and developing 
autophagosome [53]. Closer analysis has revealed specialised regions dubbed 
‘omegasomes’ which serve as a sort of surrounding ‘cradle’ as the 
autophagosome forms. Importantly, these omegasomes are rich in 
phosphatidylinositol-3-phosphate PI(3)P, which allows for the recruitment of 
numerous members of the autophagy machinery to promote autophagosome 
completion [52, 54]. However, other sources have also been suggested with 
compelling evidence to be involved in this early stage of the process. Several 
members of the autophagy machinery have been shown to localise to the 
mitochondria outer membrane, and the organelle is suggested to be able to 
provide a supply of lipids for autophagosome formation [55]. The plasma 
membrane has also been implicated, with endosomes containing plasma 
membrane derived material appearing to facilitate the delivery of certain Atg 
proteins to where they are needed [56, 57]. Much like the plasma membrane, 
some golgi derived proteins have been linked to Atg protein shuttling [58, 59]. 
So, how can we accommodate all these suggested locations of the 
autophagosomes’ origins? It is likely that all the proposed sites do indeed 
contribute to the process, with possible cell type or context specific differences 
determining the donor. In some cases, autophagosomes may arise from a 
mixture of sources. Indeed, ER: mitochondria contact sites have been identified 
as regions of autophagosome formation [60], a finding that potentially both 
reconciles the work of the groups earlier mentioned, and gives an indication that 




Master regulators of autophagy 
Of all the regulators of autophagy initiation, by far the best characterised is the 
Target Of Rapamycin (TOR) complex. In mammals this is known as mTOR 
(mechanistic target of rapamycin, formerly mammalian target of rapamycin). 
mTOR is a master regulator of cell growth and proliferation, and detects signals 
from a diverse range of sources [61]. These include factors related to cellular 
energy and metabolism, such as growth factors, amino acids, and ATP; as well 
as signals associated with stress, including DNA damage and the oxidative 
state [62, 63]. More specifically, mTOR is a serine/threonine protein kinase 
consisting of two subunits, mTORC1 and mTORC2, which exert effects on 
downstream targets and substrates via different phosphorylation cascades [64, 
65]. mTOR activation begins with the upstream ligation of growth factors to their 
receptors. This in turn activates the Class I Phosphoinositide 3-kinase (PI-3K) 
and Akt kinases, which induce mTOR signalling via inhibition of the mTOR 
negative regulator Tuberous Sclerosis (TSC) 2 [66-68]. Owing to its role as a 
key promoter of cell proliferation, many mTOR substrates are involved with 
ribosomal translation and protein synthesis, with two of the most notable 
examples being S6K1 and 4E-BP1 [69, 70]. Given these effects, it is not 
surprising that mTOR over-activation has been linked to the development of 
several tumours, and represents a key target for many chemotherapeutic 
strategies [61, 71]. 
Whilst mTOR activity is promoted under periods of growth, it is often 
downregulated during times of stress, such as DNA damage and starvation [72]. 
Consistent with this, under normal conditions mTOR serves as a repressor of 
autophagy induction. However, under certain stimuli, like the aforementioned 
stresses, mTOR activity is itself inhibited, and autophagy can proceed [73].  
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Of the two subunits, mTORC1 appears relevant to autophagy. mTORC1 is itself 
a composite of different components, namely mTOR, rapamycin-associated 
protein of TOR (Raptor) and GβL [64]. The complex exerts its repression on 
autophagy by directly phosphorylating the initiator of the autophagy cascade, 
the ULK complex (which will be described in more detail in the following section) 
[74]. When autophagy is needed, mTOR can be deactivated by proteins such 
as the energy sensing AMPK. During periods of nutritional shortage, AMPK can 
promote the expression of TSC2 which negate mTOR and release the ULK 
complex [75]. Chemical strategies of mTOR inhibition also exist, most famously 
from the complexes namesake, rapamycin [76]. Rapamycin and its various 
homologues (often referred to as ‘Rapalogs’) inhibit mTOR and subsequently 
have become popular methods of artificially inducing autophagy [77]. 
It is worth noting mTOR is not the sole autophagy regulator. A number of 
independent signals have also been identified [78, 79]. Increases in intracellular 
Ca2+, inositol and cyclic AMP (cAMP) have all been demonstrated to repress 
autophagosome formation [80, 81]. Alternatively, c-Jun N-terminal kinase (JNK) 
can liberate some components of the autophagy machinery and promote 
autophagosome formation [82]. Since mTOR has such broad-reaching influence 
across numerous aspects of cell biology, these independent mechanisms may 
provide more therapeutic appeal, with less risk of off target effects. These 
routes may bear particular relevance to certain pathologies, such as the 
elevated Ca2+ levels associated with excitotoxic neuron damage, and the 





Autophagy initiation and formation of the autophagosome 
The process of autophagosome formation is carried out by a dedicated protein 
family referred to as the Atg proteins. Around 40 members of this group have 
currently been identified and described, with those seen in yeast largely having 
homologues right through the evolutionary tree to mammals [10]. 
Autophagosome formation proceeds through the sequential activation of a 
series of complexes, which can largely be divided into three main events - 1) 
initiation via the ULK complex, 2) nucleation of the forming autophagophore via 
the Beclin1-PI3K Class III complex and 3) elongation to the double membraned 
autophagosome via two ubiquitin-like conjugation processes- ATG12-5-16L1 
and LC3-PE (summarised in Fig 2) [83].  
Autophagy initiation is regulated by the ULK complex, which consists of the 
mammalian homologue of Atg1-ULK1 (and ULK2)-, ATG13, ATG101 and Focal 
Adhesion Kinase Family Interacting Protein of 200kD (FIP200) [47, 84]. When 
mTORC1 is active, it associates with and phosphorylates ULK1 and ATG13, 
inhibiting their function [85]. However, during conditions whereby mTORC1 is 
inhibited, ULK1 and ATG13 are released and translocate to the membrane from 
which the autophagosome will be born. ULK1 is a serine/threonine kinase which 
autophosphorylates when active. Other studies indicate the energy sensing 
AMPK is also able to phosphorylate ULK1 for it to carry out its function [45, 46]. 
The now active ULK phosphorylates the other members of the complex, with 
ATG13 facilitating the interaction between ULK and FIP200 [86]. ATG101 
stabilises the ULK and ATG13 binding [74, 87].  
In addition to phosphorylating its own complex, ULK1 also phosphorylates and 
activates components of the next mediators of autophagosome formation- 
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AMBRA and Beclin-1 of the downstream Beclin1-PI3K Class III Complex [85, 
88-91]. The phosphorylated Beclin-1 activates other components of the PI-3K 
Class III Complex, including Vps34. Vps34 is the only Class III PI-3K found in 
mammals, and catalyses the generation of PI(3)P [92-94]. In the context of 
autophagy, PI(3)P generation on the isolation membranes acts as a recruiter 
and scaffold for various effectors necessary for membrane nucleation and 
elongation, including FYVE domain containing proteins (such as DFCP1) [52], 
and WD Repeat Domain Phosphoinositide-Interacting (WIPI) proteins [95-97]. 
Some WIPI proteins for instance, are believed to be involved in the recruitment 
of ATG12-5-16L1 conjugate to the isolation membrane [98]. The ATG12-5-16L1 
conjugate is formed through the actions of other Atg proteins acting in roles 
comparable to E1 and E2 enzymes in the ubiquitination process. First, the C-
terminal of ATG12 is activated by ATG7 (E1-like), and then it is transferred and 
conjugated to ATG5 via ATG10 (E2-like) [42, 99-102]. The ATG12-5 conjugate 
then complexes with ATG16L1 [44, 103]. In the second ubiquitin-like 
conjugation process, LC3 is cleaved by ATG4, converting it to LC3-I. LC3-I then 
undergoes ubiquitin-like modifications, mediated by ATG7 (E1-like) and ATG3 
(E2-like). The ATG12-5-16L1 conjugate serves an E3-like enzyme role in LC3 
processing; interactions between ATG12 and ATG3 bring LC3 to the isolation 
membrane, whereupon it is lipidated by PE to form LC3-II. Upon completion of 
autophagosome formation, the ATG12-5-16L1 conjugate dissociates, whilst 
LC3-II remains. This makes LC3-II a useful and widely used marker of 
autophagy [43, 104-106] (summarised in Fig 2). 
Autophagosome-lysosome fusion 
Once fully formed, autophagosomes need to be delivered and fused to 
lysosomes, whereupon their degradation can take place. Until relatively recently 
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our knowledge of this process was limited, but several studies have highlighted 
some key mediators. As autophagosomes are formed throughout the cytoplasm, 
they must first be delivered to the perinuclear regions where lysosomes are 
found. This is achieved via the microtubule (MT) network, with the 
autophagosomes shuffled along MTs in a dynein dependent manner [107-109].  
A number of proteins have been implicated in the actual fusion event between 
autophagosome and lysosome. The main players appear to be members of the 
Soluble N-ethylmaleimide-Sensitive Factor Attachment Protein Receptor 
(SNARE) family. SNAREs exist as t-SNAREs (on the target membrane), and v-
SNARES (vesicle membrane), which together form a tether between structures. 
In the context of autophagy, Syntaxin-17 (STX17) on the autophagosome and 
Vesicle-associated membrane protein 8 (VAMP8) on the lysosome appear to be 
the main t- and v-SNAREs respectively [110]. When needed, STX17 appears to 
be recruited to autophagosomes from the ER, mitochondria and cytosol. Here, it 
interacts with Synaptosome-associated protein 29 (SNAP29), which facilitates 
its binding with VAMP8 on the lysosome to complete the tether [11, 111, 112]. A 
number of other factors have been identified that also aid and fortify this 
interaction. The Homotypic fusion and protein sorting (HOPS) complex is 
involved in endosome to lysosome binding events, but has also been shown to 
function in autophagy also [113]. More specifically, the HOPS complex is 
composed of 6 separate subunits (VPS11, 16, 18, 39, 41, and 33A), of which 
VPS16 and VPS33A seem necessary for autophagy. HOPS interacts with 
STX17 following its localisation to autophagosomes, and aids in the subsequent 
tethering between SNAP29 and VAMP8 [110, 114, 115]. Other notable 
mediators include Atg14, which again serves to stabilise the connection 
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between STX17 and SNAP29 in preparation for the VAMP8 lysosomal fusion 









Our greater awareness of the interactions between autophagosome and 
lysosome has allowed for the development of strategies to disrupt this process. 
For instance, genetic ablation of STX17 and VPS33A results in a blockade to 
autophagosome-lysosome fusion, generating large accumulations of non-
degraded autophagosomes [110, 112].  
Another important factor in the proper degradation of autophagosomes is the 
state of the lysosome itself. Lysosomes are acidic vesicles, with their pH and 
resident enzymes (some 50+ hydrolases) needed to fulfil their degradative 
function [117, 118]. The pH of these organelles is maintained via the Vacuolar 
H+ ATPase (V-ATPase), a proton pump found on the outer lysosome 
membrane [119]. Although the lysosomes consist of many different proteins, the 
most abundant are the lysosomal associated membrane proteins 1 and 2 
Figure 3: Regulation of autophagosome-lysosome fusion 
Fusion between autophagosome and lysosome is largely mediated by members of the 
SNARE protein family. A Syntaxin17 (STX17) is recruited to fully formed autophagosomes. 
Other proteins, including VPS16 and VPS33A of the HOPS complex, as well as Atg14, 
facilitate the binding between STX17 and cytoplasmic SNAP29. B The fusion between 
autophagosomes and lysosomes can be completed via the now bound STX17 and SNAP29 
interacting with VAMP8 on the lysosome membrane (summarised in C). D The end result is 
the autolysosome, and degradation follows. 
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(LAMP1/2), which have been estimated to make up around 50% of the 
organelle’s outer membrane. Because of this, LAMPs are popular markers for 
assessing the state and distribution of the lysosome [120]. In the context of 
autophagy, LAMP1/2 appear to aid in the trafficking of lysosome to 
autophagosome [107, 109]. We can manipulate these various traits of the 
lysosome to disrupt autophagy flux. For instance, one of the most commonly 
used approaches for inhibiting autophagosome degradation is the use of the 
chemical agents bafilomycin-A1 (baf) and chloroquine (CQ), which both perturb 
lysosomes by raising their pH. Baf is an inhibitor of the V-ATPase proton pump 
[121]. As a weak base, CQ can freely enter the lysosome, whereupon it is 
protonated and accumulates, again resulting in an elevation of pH [122, 123]. 
Genetic disruption of the LAMP proteins causes dysfunction between the 
trafficking of lysosome to autophagosome, and thus an overall decrease in 
autophagy flux [109]. 
Material degraded by autophagy is released to form new amino acids for the 
use of the cells [124]. Therefore, the process can be thought of as a form of 
waste recycling system, providing fresh material for the cell to utilise.  
Bulk degradation or selective targeting? 
Classically autophagy was viewed as a method of large scale bulk degradation 
of portions of the cytoplasm, in contrast to the more selective and smaller scale 
UPS [4]. However, a wealth of recent studies have shown that in many 
instances, autophagy does have a selective element [125]. An ever expanding 
list of autophagy adaptor proteins have been identified, which label specific 
targets for autophagosome capture [126]. These adaptors are then engulfed 
along with the target material, and subsequently taken to the lysosomes for 
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degradation. Common features shared across these adaptor proteins is a 
cargo-associating domain, which binds to the target material, as well as an LC3-
interacting region (LIR), allowing for the linkage to the autophagosome 
(summarised in Fig 4) [127]. In many cases cargo recognition between 
adaptor and target is mediated by ubiquitin, much like with the UPS [128, 129]. 
Although there may be a degree of competition between the two systems for 
ubiquitinated substrates, the UPS can only accommodate smaller material, 
whilst autophagy can capture bulkier targets [130]. The list of autophagy 
adaptor proteins now numbers more than ten, with the first identified and most 
well-known being sequestosome 1 (p62), which aids in the recognition and 
clearance of numerous substrates [125]. Because of this role, p62 is commonly 
used to help assess the state of autophagy flux. As p62 is degraded along with 
the target material it labels, higher levels of p62 are indicative of a blockade to 
autophagy degradation [131]. 
Given the importance of these adaptor proteins in autophagy clearance, it is 
unsurprising that mutations to them result in the development of some 
pathologies. To continue with the case of p62, its mutations have been linked to 
Paget’s disease of the bone, as well as neurodegenerative disorders such as 
amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD) [132].  
With the discovery of the various mechanisms involved in ‘selective autophagy’, 
has come the identification and subdivision of different specialised types of the 
process. These include ‘aggrephagy’ (for bulk protein aggregates), mitophagy 
(for mitochondrial clearance), pexophagy (perixosomes), ribophagy (ribosomes), 
ERphagy (ER), lipophagy (lipids), nucleophagy (nuclear envelope) and 













Manipulating autophagy- common drugs and targets 
Our increased understanding of the machinery involved in autophagy regulation 
has helped in the identification of chemical agents to manipulate the process. 
Generally, autophagy can be altered at two stages: either at the initial 
autophagosome synthesis step, or at the later process of autophagosome-
lysosome fusion.  
Typically, methods to chemically induce autophagosome synthesis have 
focused on inhibiting mTOR, the master repressor of the process. The most 
commonly used such autophagy inducer is rapamycin. Rapamycin or its 
derivatives (known as rapalogs) have aided our understanding of autophagy 
Figure 4: Specific adaptor proteins allow for a selective form of 
autophagy 
A number of autophagy adaptor proteins have been identified, with the most well-known 
being p62. These proteins share the common features of a cargo-associating domain, 
which interacts with the target material, and the LC3-interacting region (LIR), which 
completes the bridge to the autophagosome. Autophagy then proceeds as usual, with the 
adaptor protein degraded along with the target material. 
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across various cell types, as well as helped elucidate some of the roles the 
process plays in disease [62, 79]. Since mTOR seems important in tumour 
growth, dual PI-3K/mTOR inhibitors like PI-103 [135] or NVP-BEZ235 (BEZ) 
[136] have been trialled as anti-cancer drugs, but also have effects on 
autophagy too. However, given that mTOR has numerous roles in addition to 
autophagy, it may not represent the most viable target for inhibition. Therefore, 
interest has grown in identifying alternative inducers of autophagy that act 
independently of mTOR [80]. There has been some success on this front, with 
several clinically approved autophagy initiators characterised. Strategies include 
lowering levels of inositol via lithium, or with drugs such as carbamazepine [78]; 
reducing intracellular Ca2+ with drugs such as verapamil [137]; reducing cAMP 
levels via imidazole activation with drugs like rilmenidine [80]; or by inhibiting 
glucose transport by trehalose [138]. 
In contrast, methods of inhibiting autophagosome synthesis by chemical 
intervention are relatively limited. The necessity of PI-3K signalling was 
established in the early days of autophagy research, with the pan PI-3K inhibitor 
3-methyladenine (3-MA) identified as an inhibitor of autophagosome synthesis 
[34]. Available strategies have not evolved much since then, with alternative PI-
3K inhibitors such as wortmannin [35] being other options that work on much 
the same mechanism. 
Inhibiting the later stage of autophagosome degradation is achieved by 
manipulating the acidic pH of lysosomes. Two commonly used agents for this 
are Baf and CQ. Baf acts as an inhibitor of the v-ATPase, a proton pump on the 
lysosome surface that usually serves to maintain the vesicle’s acidity [121]. 
Similarly, CQ is a lysosomotrophic base that can freely enter and accumulate 
within the lysosome, again elevating the pH [139]. 
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For ease of reference, a table has been provided summarising the intracellular 
targets and effects on autophagy of all the drugs used in this study (Table 1).  
Table 1: Summary of the autophagy manipulating drugs used in this study 
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1.4: Autophagy in health and disease 
Over the past decade or so, the interest in autophagy has exploded, helped in 
no small part by its implications in an astonishing number of pathologies. 
Perhaps the most dramatic example of its importance is that knockout of certain 
members of the autophagy machinery are embryonic lethal in mice, such as 
beclin1 [140], FIP200 [141] and AMBRA [90]. Although mouse knockouts for a 
number of other autophagy genes survive to birth, they display neonatal death. 
Examples include Atg3 [142], Atg5 [143], Atg7 [144], Atg9 [145] and Atg16L1 
[146]. These instances make it strikingly clear that autophagy plays vital roles in 
cell survival. But how is this achieved? 
A common feature observed across the neonatal lethal autophagy knockouts is 
a deficiency of amino acids, exerting a negative impact on protein synthesis, 
and ultimately leading to death [48]. Autophagy has been recognised as a 
response to starvation and a source of amino acids since the early years of the 
field, with nutrient deficiency identified as a potent stimulator of autophagosome 
synthesis [14]. These rodent knockout models highlight how vital this amino 
acid supply is for survival. Unsurprisingly, similar results are seen across all 
model organisms [147-149].  
However, autophagy also serves another vital pro-survival function in addition to 
an energy supply. The persistence of aberrant or faulty cytoplasmic material 
can be disastrous for cell health, perhaps most notably the mitochondria. These 
organelles control a number of cellular roles, including metabolism and cell 
death [150, 151]. If not removed, damaged mitochondria can initiate cell death 
via apoptosis [152]. Alternatively, dysfunctional metabolism can promote the 
generation of reactive oxygen species (ROS), which are also cytotoxic and can 
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induce lethality [153]. Therefore, the clearance of mitochondria by autophagy 
(more specifically in this case, ‘mitophagy’) is vital to prevent this [154]. In a 
similar vein, stress to the ER can also be a risk to cell survival, with this 
exacerbated in autophagy-null conditions [155-158]. The clearance of 
potentially harmful waste material by autophagy isn’t just limited to organelles. 
Indeed, the failure to remove certain aggregate prone proteins is relevant in the 
progression of neurodegenerative diseases, which will be addressed later in this 
section [18, 159, 160].  
Befitting such an ancient process, autophagy has been implicated in a wealth of 
pathologies. For instance, as an important response to starvation, it is perhaps 
not surprising that autophagy dysregulation seems involved with some 
metabolic disease [161-163]. However, its influence spreads to an astonishingly 
diverse ranges of fields, hence a relatively recent explosion in interest. 
Autophagy seems important in the field of infection and immunity. A specialised 
type of autophagy dubbed ‘xenophagy’ can be deployed by cells to capture 
invading bacteria and viruses and destroy them [19, 164, 165]. Both innate and 
adaptive immune responses benefit too from the process. Autophagy can signal 
to components of the innate immunity machinery [166], and present antigens to 
Major Histocompatability Complexes (MHCs) in the adaptive system [167, 168]. 
Interestingly, some pathogens have also evolved methods to hi-jack the 
autophagy process to aid their spread, which is testament to the benefits 
autophagy can bring to survival [169-171]. 
Given autophagy’s roles in both maintaining cellular homeostasis, as well as 
staving off numerous diseases, it has attracted interest with groups researching 
the ageing process. Calorific restriction has been demonstrated to improve the 
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health-span of animal models ranging from Caenorhabditis elegans right 
through to non-human primates, with autophagy upregulation a postulated 
mechanism behind this benefit [172]. In accordance with this, the extent of 
autophagy activity has been noted to decrease with age [173, 174]. Also, two of 
the major pathologies that manifest with older age- cancer and 
neurodegeneration- can be delayed or safeguarded by enhanced autophagy [17, 
18, 159, 175]. Indeed, it is these two fields of disease research that are most 
relevant to this study, and as such, will now be reviewed in more detail. 
1.5: Autophagy and cancer 
Of all the diseases autophagy has been implicated with, perhaps the most 
extensively studied is the roles it plays in cancer. It also happens to be one of 
the most complex of such relationships, with dramatically different influences on 
the disease depending on the context [176]. Despite this difference, autophagy 
does appear to serve the same overall purpose: to promote cell survival. In 
normal cells, this means the successful maintenance of cell homeostasis and 
disposal of waste material, roles which help prevent the formation of tumours 
[17, 177]. However, once such a malignancy has developed, autophagy will 
also act to promote its survival too; it can supply material to suit the tumours 
ever increasing energy demands, as well as remove harmful species this 
expansion may generate [178, 179]. Therefore, autophagy has come to 
represent something of a ‘double-edged sword’ in the field of cancer.  
Autophagy in tumour prevention 
Owing to both the actions of its regulators, as well as the homeostatic functions 
it serves in the cell, autophagy has been demonstrated to aid in suppressing the 
formation of tumours. For instance, a few members of the autophagy machinery 
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have been identified as tumour suppressor genes. Perhaps the most notable 
example is the key autophagosome formation protein beclin1. Allelic loss of 
beclin1 is seen in 40-75% of human breast, ovarian and lung cancers [180-183]. 
This finding is strongly replicated in mouse models, with beclin1 deficiencies 
elevating the number of tumours formed in animals, whilst overexpression 
appears protective [17, 140, 184]. Loss of another autophagy protein, Atg4C, 
yields similar results [185]. Mutations to other Atg family members (Atg2B, 5, 9B, 
12) are associated with gastric and colorectal cancer [186]. In the same vein, it 
is worth noting that autophagy inhibitors such as the PI-3K/mTOR signalling 
pathway are also oncogenic, and over-activated in many tumours [187]. 
From a more mechanistic perspective, autophagy can prevent tumorigenesis 
via its duties in stress resistance and waste clearance. Genomic damage and 
the subsequent chromosomal instability are major risk factors for tumour 
formation, with several studies highlighting autophagy’s importance in negating 
these events. Downregulating autophagy via depletion of beclin1 or Atg5 
renders cells more susceptible to metabolic stresses, which in turn cause DNA 
damage and risk of tumourigenesis [188, 189]. Other risk factors for DNA 
damage, such as ROS (and their source, faulty mitochondria) are also targeted 
by autophagy.  Potentially hazardous inflammatory responses can be repressed 
by autophagy. Interestingly, the autophagy adaptor and substrate p62 has been 
identified to be dangerous to the cell if left to aggregate. Persistence of p62 
appears to promote organelle damage, such as to the ER and mitochondria, 
generating oxidative stress [177]. At the same time, the protein is also able to 
signal to the oncogenic regulators Ras and NF-κB [190]. Therefore, a well-
functioning autophagy pathway keeps p62 levels in check, and prevents any of 
these events occurring. 
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Tumour growth and autophagy addiction 
Whilst autophagy helps prevent the formation of tumours, once such a 
malignancy has developed the outcome of the process is dramatically different. 
Various limitations that can hinder tumour growth, such as a steady nutrient 
supply, as well as resistance to the often hypoxic microenvironment their 
excessive expansion generates, can be bypassed by autophagy [178, 191-193]. 
Therefore, rather than preventing the disease, autophagy provides a vital lifeline 
to a number of cancers. Certain tumours are said to be ‘autophagy addicted’, 
and utilise signalling routes to manipulate the process for their own gain. For 
instance, tumours driven by the oncogene Ras display upregulated autophagy, 
which aids malignant transformation [191, 194]. Distance from an oxygen 
supply is usually a barrier to continued cell expansion; both as oxygen is 
necessary for ATP production in the electron transport chain, and also hypoxia 
elevates the risk of organelle damage and free radical production [192, 195, 
196]. Autophagy can alleviate both of these limitations. The material it recycles 
can feed into the quicker but less sustainable glycolysis, which tumours favour 
for their growth [193]. At the same time, the clearance of damaged organelles, 
particularly the ER and mitochondria, protects against the generation of harmful 
species or triggering of stress responses [195]. In accordance with this, 
hypoxia-inducible factor 1α (HIF1α) has been identified as a trigger of 
autophagy, thus providing a mechanism for tumours to manipulate the process 
[192].  
As well as enabling the continued growth of tumours, the pro-survival nature of 
autophagy can also pose a barrier to chemotherapeutic strategies. Common 
mechanisms to try and eliminate tumours, such as by causing DNA damage or 
eliciting cell death by apoptosis, are bypassed by the process [152, 192, 196]. 
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However, on the same rationale, methods of disrupting autophagy could 
remove such benefits and therefore render tumours susceptible to such 
treatments. An additional attraction to this approach is that it may pose 
selectivity against malignancies, with them being far more reliant on autophagy 
as a survival crutch than the healthy surrounding cells. This would be especially 
true for the hypoxic regions, which have thus far proven difficult to tackle with 
conventional therapies or surgeries [176]. Studies into depleting autophagy at 
either the autophagosome formation step or the lysosomal degradation process 
have been carried out in a wealth of tumour models and types. Positive results 
have been observed in cancers of the pancreas, chronic myelogenous 
leukaemia (CML) [197], lymphoma [179], breast [198], glioblastoma multiforme 
[199], prostate [200], hepatocellular carcinoma (HCC) [201-203], colon [204], 
eosphagus [205], and more [206]. Interestingly, autophagy inhibition has also 
been found to enhance previously existing chemotherapeutic approaches when 
used in combination treatments. For instance, the medically approved CQ 
boosts the cell death caused by 5-fluorouracil (5FU) in colon cancer and HCC 
[203, 204]; it also combines with the popular dual PI-3K/mTOR inhibitors to 
pose greater toxicity against drug resistant gliomas and peripheral nerve sheath 
tumours [206]; and HER2 breast carcinoma’s resilience against trastuzamab is 
lost when used in synergy with CQ [207]. Similar findings have also been made 
for radiotherapy; again inhibiting late stage autophagy with CQ augments 
sensitivity in tumours including glioma and CML [197, 199]. 
Current outlook 
Although for many diseases the general lessons learnt so far are to promote 
autophagy for treatment, a greater degree of caution is needed for cancer. 
Efforts to maintain a healthy level of autophagy may well reduce the risk of 
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tumour onset for the individual, but this could prove catastrophic if continued 
following malignant formation. However, with tumours often exhibiting elevated 
autophagy, disruption of the process represents an exciting potential angle for 
more cancer specific treatment strategies. Promising findings in treating 
previously resistant malignancies through combining existing 
chemotherapeutics and autophagy inhibitors raise further important questions to 
be answered. Does the extent of autophagy activation determine the application 
of these treatments? Could they be applicable to most, if not all, previously 
resistant tumours? For instance, many tumours can continue to grow 
unchecked and resist chemotherapies owing to mutations in the programmed 
cell death (PCD) mechanism apoptosis. Does disrupting autophagy somehow 
reactivate apoptosis, or does it help execute cells through alternative means? 
This latter question will be addressed in more detail in Section 1.8 and is one of 
the key areas of interest of this thesis. 
1.6: Autophagy and neurodegeneration 
One of the most exciting fields of autophagy research to emerge over the past 
fifteen years or so is the role the process plays in the onset and progression of 
various neurodegenerative diseases. Autophagy runs rapidly and efficiently in 
neurons, indicating its importance in maintaining homeostasis of these cells 
[208-210]. Given this, it is not surprising that a wealth of studies indicate that 
autophagy serves a protective and pro-survival function for neurons. This is 
perhaps most dramatically illustrated by autophagy defective mouse models, 
with knockout of Atg7 and Atg5 each resulting in neuron loss coupled with 
behavioural and motor abnormalities [211, 212]. Indeed, the overall level of 
autophagy activity has been observed to decrease as we age [174]. But what is 
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the mechanism underlying autophagy’s protection? A common feature shared 
across a large number of neurodegenerative pathologies is the occurrence of 
toxic protein aggregates, which drive the disease progression and the eventual 
neuron loss. Strikingly, every one of these toxic aggregates has been shown to 
be subject to autophagic clearance [18, 159, 213]. Therefore, much interest has 
turned towards identifying strategies of promoting autophagy in neurons for 
potential therapeutic options. This section will focus on the current evidence and 
progress on the benefit of autophagy in three of the major neurodegenerative 
disorders- Huntington’s Disease (HD), Parkinson’s Disease (PD), and 
Alzheimer’s Disease (AD). 
Huntington’s Disease 
Huntington’s disease (HD) is an autosomal dominant disease that is associated 
with both movement disorder and cognitive decline. The striatum is the most 
sensitive brain region to HD toxicity, in particular the medium spinal neurons.  
HD pathology typically manifests in patients between the ages of 35-50, but 
severe cases can develop in childhood. After about 15-20 years from onset, the 
disease proves fatal [214].  
HD is caused by mutations to the Huntingtin protein. Huntingtin contains a 
region consisting of a series of CAG repeats, encoding polyglutamine. In 
healthy individuals, these repeats will number 35 or less. However, 36+ CAG 
repeats results in HD onset, with a greater number of repeats leading to an 
earlier age of onset. This mutant form of the protein has a greater propensity to 
form aggregates, that go on to cause neuron toxicity [138, 215]. These mutant 
huntingtin aggregates have been shown to be targeted by autophagy for 
clearance across a number of different experimental models [18]. Excitingly, 
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efforts of promoting autophagy have been associated with improvements in HD 
pathologies. The first such evidence of this came through the use of rapamycin, 
which caused increased clearance of huntingtin aggregates and a 
corresponding degree of recovery in behavioural and motor tests in a HD 
mouse model [18]. Subsequently, other clinically approved autophagy inducers 
such as rilmenidine [216], trehalose [217] and verapamil [80] have also proved 
to afford similar effects in disease alleviation. Likewise, under the contrasting 
conditions of autophagy inhibition, both disruptions to autophagosome synthesis 
and degradation cause a failure in huntingtin clearance [18]. 
Interestingly, despite autophagy being protective against the pathology, HD 
models are generally associated with increases in numbers of cytoplasmic 
autophagosomes. However, close analysis has shown many of these vesicles 
to be ‘empty’, suggesting a defect in cargo recognition occurs in HD, leading to 
the persistence of the toxic aggregates [218]. Indeed, recent work has 
highlighted that the wildtype form of the huntingtin protein is important for the 
process of selective autophagy; serving as a linker between autophagosomes 
and the classic autophagy adaptor p62 [219, 220]. Therefore, when the protein 
is mutated this role cannot be fulfilled, hence the failure to clear the toxins. 
Parkinson’s Disease 
Parkinson’s Disease (PD) is the second most prevalent neurodegenerative 
disease, and is typified by bradykinesia and tremors [221]. Both familial and 
sporadic instances of PD occur, with the bulk of cases representing the latter 
(~90%) [222]. The disease results from a loss of dopaminergic neurons in the 
substantia nigra within the striatum. As with other neurodegenerative diseases, 
a key hallmark of PD is the appearance of cytoplasmic protein aggregates. In 
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the case of PD, the aberrant protein is α-synuclein, which forms inclusions 
known as lewy bodies [223]. With both genetic models and those utilising 
neurotoxins to mimic sporadic PD, α-synuclein has been found to be targeted 
by autophagy for clearance [224]. Treatment with autophagy inducers like 
rapamycin aid aggregate removal [159, 225, 226], whilst the inhibitor 3-MA has 
the opposite effect [227]. In addition to the removal of α-synuclein, autophagy 
also helps prevent the onset of PD through the disposal of faulty mitochondria 
(mitophagy). Mitochondrial disorders can be an important trigger in PD. 
Although only a minority of disease cases are from genetic abnormalities [222], 
two protein mutations associated with the pathology relate to autophagy’s 
targeting of mitochondria-PTEN-induced putative kinase 1(PINK1) and parkin. 
PINK1 recruits cytoplasmic parkin to the mitochondrial outer membrane, 
whereupon it acts as a ubiquitin ligase for autophagy recognition. Defects to this 
system means faulty mitochondria persist, which can potentially produce 
harmful ROS [228, 229]. 
As with HD, despite the clear protective roles autophagy serves in PD, 
autophagosome accumulations are observed in various models of the disease, 
as well as in post mortem human brains [230]. However, rather than an excess 
of autophagy activity, these appear to be the result of perturbations to 
autophagy flux. Both PD associated neurotoxins as well as α-synuclein itself 
have been found to block the late stage of autophagosome degradation [231]. 






Alzheimer’s Disease (AD) 
Alzheimer’s Disease (AD) is the most common form of dementia, and proceeds 
through the progressive loss of neurons. AD is associated with accumulation of 
two different aberrant proteins: extracellular plaques of amyloid-beta (Aβ), and 
cytoplasmic neurofibrillary tangles (NFTs), composed of aggregates of mutated 
Tau [232]. Both of these proteins can be captured and cleared by autophagy, 
which therefore protects neurons from the potential formation of toxic 
accumulations [160, 233]. Consistent with this, post mortem brains of AD 
patients show reduced levels of the autophagy protein beclin1. This is replicated 
in AD mouse models, with beclin1 depletion exacerbating the 
neurodegenerative phenotype [234]. Conversely, addition of the autophagy 
inducer rapamycin promotes clearance of both Aβ and Tau, which is coupled 
with improvements to memory and learning in AD mice [175, 235].  
As with the other neurodegenerative conditions, autophagosome accumulations 
are observed in the AD brain [213, 233]. Much like with PD, these seem to be a 
result of a blockade to the degradation step of autophagy, meaning that the 
toxic proteins can persist and cause neuron damage [209]. This risk factor 
seems especially prevalent for AD: autophagosomes can sequester the 
machinery needed to process precursors of Aβ to its pathological form. 
Therefore, retaining non-degraded autophagosomes enhances the formation of 







It is both exciting and promising to observe autophagy elevation to have a 
similar effect and benefit across the major neurodegenerative pathologies. 
Notably, these have been achievable in animal models with medically approved 
drugs, which bodes well for potential future application.  An interesting point to 
clarify will be if increased autophagy does indeed always have a positive 
outcome for these disorders. As discussed, all of HD, PD and AD are linked 
with a fault to the process (cargo recognition in the former, lysosomal fusion the 
latter two), and this may affect which treatments are suitable for the disease. As 
autophagy is a dynamic process, context seems a very important determinant in 
its effects. Failure to properly address this could have disastrous consequences 
(discussed in more detail in Button et al., (2015) in Appendix ii). 
1.7: Programmed cell death 
Programmed cell death (PCD) is critical in the development and maintenance of 
metazoans [236].  
Classically, PCD was divided across three classes. Class I referred to the most 
well-known mechanism of cell death, apoptosis, and was typically identified via 
the involvement of caspase proteins as well as morphological features like 
chromatin condensation and cell shrinkage. Class II covered autophagic cell 
death, which applied to instances of dying cells displaying large numbers of 
cytoplasmic autophagosomes. Finally, class III encompassed necrotic death, 
largely seen as chaotic, uncontrolled, and associated with inflammation. 
However, with our expanding knowledge of the process, these classifications 
have proven flawed, and fittingly, the class divisions in this way have been 
abandoned [237]. As will be discussed at length throughout this thesis, the 
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concept of autophagy as a route of PCD has been deeply controversial, with 
many critics arguing the autophagosome accumulations are merely an attempt 
at rescuing already doomed cells, rather than directing the cell death 
themselves [20, 22, 25-27]. Also, the idea of necrosis being chaotic has also 
been challenged, with the identification of a programmed form of necrotic cell 
death, necroptosis [238]. Finally, a wealth of other potential cell death routes, all 
with their own subtle differences, continue to be classified [239]. Whilst there 
may be a degree of overlap and redundancy between these routes from 
miscommunication between research groups, they still highlight how our 
previous view of PCD was an oversimplification. 
In this section, we will largely focus on the regulation of the major PCD routes, 
apoptosis and necroptosis. After this, we will go on to address the more 
controversial topic of the potential role the usually pro-survival autophagy may 
have in cell lethality. 
Apoptosis 
The most iconic and well-studied form of cell death is apoptosis. 
Morphologically, cells undergoing this process display a number of hallmark 
features. These include cell shrinkage, nuclear chromatin condensation and 
fragmentation, and membrane blebbing [240, 241]. Although this process has 
different modes of activation, all instances are unified by the involvement of 
caspases (whose name derives from cysteine protease with aspartate 
specificity). To prevent premature lethality, these proteins are generated as 
inactive precursors in the cytosol, consisting of a prodomain (of varying length), 
then a large and a small subunit. Caspases are activated when their prodomain 
is cleaved, either by other proteins or another caspase. The currently known 
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caspases can be broadly divided into two groups based on their function in 
apoptosis –‘initiator caspases’, which serve to cleave and activate further 
downstream ‘executor caspases’, which go on to undertake the cell death by 
targeting nuclear and structural proteins [242-244]. With caspases being a 
necessity for apoptosis to be carried out, the process can be depleted artificially 
via strategies that inhibit these proteases. The chemical zVAD-fmk (zVAD) is a 
pan-caspase inhibitor, and therefore is able to inhibit apoptosis [245]. In addition, 
genetic strategies using RNAi against certain caspases can also reduce cell 
death by this mechanism [246]. 
Apoptosis can be activated by two differing signalling routes: extrinsic apoptosis, 
which responds to extracellular signals (Summarised in Fig 5); and intrinsic 
apoptosis, which is elicited by intracellular stresses (Summarised in Fig 6). 
Extrinsic apoptosis 
Extrinsic apoptosis is mediated by various death receptors located on the cell’s 
plasma membrane, which become activated following the binding of certain 
extracellular stress signals. Death receptors consist of an extracellular ligand 
binding region, then a transmembrane domain, and finally intracellular death 
domains (DD), which bind cytoplasmic effectors necessary to carry out the 
apoptotic activation cascade. Examples of such receptors include Fas/CD95 
(activated by Fas ligand), TNF (tumour necrosis factor) related apoptosis 
inducing ligand (TRAILR1/DR4) (activated by TRAIL), TRAILR2/DR5 (activated 
by TRAIL) and TNF receptor 1 (TNFR1) (activated by TNF-α) [237, 240, 247]. 
The intracellular events that transpire following receptor activation vary 
depending on the route. In the case of Fas and the TRAIL receptors, after 
ligand binding the adaptor Fas associated protein with a death domain (FADD) 
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is recruited via its DD. FADD serves as a platform to recruit and activate the 
initiator caspase(s), caspase8 (and in some cases caspase10), forming the 
death-inducing signalling complex (DISC). In turn, caspase8 in the DISC 
processes executioner caspases, most notably caspase3, which then goes on 
to enact apoptosis (summarised in Fig 5) [248-250].  
Extrinsic apoptosis via TNFR1 begins with the recruitment of the adaptor TNFR-
associated death domain (TRADD). As with FADD, TRADD binds to the 
receptor via its own DD. TRADD recruits receptor interacting protein 1 (RIP1), 
TNFR-associated factor (TRAF) 2 and 5, as well as cellular inhibitors of 
apoptosis proteins (cIAPs). This cluster of proteins, dubbed ‘complex I’, can be 
involved in additional cell signalling roles such as in the NF-κB pathway. 
However, when functioning in cell death, complex I is internalised and recruits 
FADD and caspase8, forming ‘complex II’. When activated, caspase8 cleaves 
and inhibits RIP1, and as before, proceeds to activate caspase3 which executes 
the cell death (summarised in Fig 5) [251-254]. 
Interestingly, the cell contains several inhibitory controls it can employ in order 
to prevent unnecessary or excessive activation of the extrinsic apoptosis 
pathway. These include decoy receptors, which have similar extracellular ligand 
binding domains as the death receptors, but lack any cytoplasmic domain and 
therefore cannot induce any caspase cascade [240]. These can compete for the 
ligands the death receptors need for their activation, and therefore reduce 
apoptotic activity. Similar mechanisms exist in the cytoplasm too; proteins like 
cellular FLICE (FADD-like IL-1β-converting enzyme) –inhibitory protein (cFLIP) 
and cIAPs compete with caspases for DD binding on adaptor proteins, again 
with the potential to reduce apoptosis [237, 253-255]. It is worth noting that 
these safeguards can be manipulated by tumours in order to afford drug 
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resistance. Many chemotherapies exert toxicity via apoptosis, and so mutations 
that promote decoy receptor overexpression, for instance, will allow for the 
tumour to survive. Other known alterations to extrinsic apoptosis seen in some 
tumours include mutations in the death receptors themselves, as well as defects 
in TRAIL transportation [241]. This highlights one of the important implications 




































Figure 5: Extrinsic apoptosis in mammalian cells 
During periods of extracellular stress, apoptosis can be initiated via the extrinsic pathway. 
This process begins with the binding of certain death ligands to their corresponding death 
receptors at their extracellular domain. How the cascade proceeds varies depending on the 
ligand/receptor pair. Instances such as Fas and TRAIL are summarised in A. Following 
receptor activation, they recruit the adaptor protein FADD via their shared death domains 
(DD). From here, FADD can process the initiator caspase, caspase-8, which in turn cleaves 
and activates the downstream executioner caspases, most notably caspase-3, which can 
then carry out the apoptotic death. Alternatively, extrinsic apoptosis can also occur via TNF 
stimulation (summarised in B). As before, the activated receptor recruits an intracellular 
adaptor, this time TRADD. TRADD in turn recruits a number of proteins, including RIP1, 
TRAF2/5 and cIAPs, forming what is known as Complex I. From here, FADD and caspase-
8 can be incorporated, with the resulting assembly dubbed Complex II. In apoptosis, FADD 
activates caspase-8, which inactivates RIP1 whilst also cleaving and activating downstream 




Apoptosis can also be activated by intracellular stresses, such as DNA damage, 
oxidative stress, and accumulation of aberrant proteins. Although caspases 
eventually carry out the cell death, the activation cascade differs from the 
extrinsic pathway. Intrinsic mechanisms of apoptosis are centred around the 
mitochondria [236]. Generally, the mitochondria membrane integrity becomes 
compromised, with many of its internal components then released to the cytosol 
and triggering the cell death response. A set of key mediators of this process 
are the highly conserved Bcl2 family of proteins, which contains both pro- and 
anti-apoptotic members. Both sets localise and act at the mitochondria 
membrane under periods of stress. Pro-apoptotic members, such as Bax and 
Bak, act to promote mitochondria outer membrane permeabilisation (MOMP), 
triggering the release of mitochondrial enzymes to the cytosol and the 
subsequent progression of intrinsic apoptosis. Anti-apoptotic members, such as 
Bcl2 and Bcl-Xl, can bind pro-apoptotic Bcl2 proteins to prevent their effects 
[256-261].  
Following MOMP, several mitochondria proteins are released into the cytosol. 
Notably, these include cytochrome-c (cyt-c), which is involved in the electron 
transport chain of oxidative phosphorylation; and Apaf1. Apaf1 binds cyt-c and 
forms a heptameric ‘wheel’ called the apoptosome. The apoptosome can then 
bind the initiator caspase caspase9, and activate it. From here, caspase9 can 
process the executioner caspase3 and apoptosis can be completed 
(summarised in Fig 6). Other mitochondrial proteins that are worthy of mention 
in apoptosis include Smac/DIABLO, which inhibits the cIAPs, therefore 
promoting caspase activation. The actual events that result in cell demise in 
intrinsic apoptosis are proposed to be linked with proteins released by MOMP 
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inducing DNA damage in the nucleus, as well as the mitochondrial dysfunction 

















Figure 6: Intrinsic apoptosis in mammalian cells 
Internal cell stresses induce apoptosis through a mechanism distinct to those from the 
extrinsic receptors. Intrinsic apoptosis is mediated via the mitochondria and the Bcl2 
protein family. Under periods of stress, two Bcl2 family proteins -Bax and Bak- are 
recruited to the outer mitochondria membrane. Together, these promote mitochondria 
outer membrane permabilisation (MOMP), leading to the leakage of some mitochondrial 
enzymes to the cytosol. Notably, these include Cyt C and Apaf1. These two proteins form 
a heptameric wheel-like structure called the ‘apoptosome’, which incorporates 
procaspase-9. The apoptosome can then process and activate this caspase, which in turn 
cleaves the executioner caspase, caspase-3, to carry out the apoptotic cell death. Other 
notable enzymes that are leaked via MOMP include SMAC/DIABLO, which inhibit cIAPs 
and therefore promote apoptosome formation, and AIF and ENDOG, which elicit further 




Alongside apoptosis, the other major known route of PCD is necroptosis. 
Although for a long period of time this pro-inflammatory form of cell death was 
deemed as chaotic, more recent work has identified a form of regulated necrotic 
death. Morphologically, cells undergoing this form of death display organelle 
and cytoplasmic swelling, and eventually rupture of the plasma membrane. 
Following rupture, the now dead cell releases ‘danger signals’ that trigger the 
innate immune response, resulting in the characteristic inflammation associated 
with necrotic death [238, 269]. 
Typically, necroptosis occurs in response to stresses such as viral infection, 
DNA damage, as well as conditions of ATP depletion and potentially high levels 
of reactive oxygen species (ROS) [270]. Several cell models for the process 
have been identified, and help aid our understanding of the mechanisms of 
necroptosis. For instance, stimulation of both mouse fibrosarcoma L929 cells 
and human Jurkat cells with TNFα leads to necroptotic rather than apoptotic 
death [271, 272]. Many more cases have since been established, including the 
mechanism of action of some chemotherapeutic drugs [273-275]. 
Initiation of necroptosis shares similarities with extrinsic apoptosis. For instance, 
two of the most commonly cited stimulators of necroptosis are TNFα and Fas 
ligand and their respective death receptors, TNFR1 and Fas/CD95 [271]. Once 
these are activated, a response similar to that outlined in the TNFR1 signalling 
in extrinsic apoptosis occurs, with the formation of complex I and then complex 
II (consisting of TRADD, FADD, caspase8 and RIP1) [255]. The decision 
between whether apoptosis or necroptosis results is dependent on events within 
this complex. RIP1 is a key mediator of necroptosis, but also a substrate of 
caspase8. Therefore, under conditions where caspase8 is active, it cleaves and 
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inactivates RIP1, suppressing necroptosis and allowing apoptosis to prevail 
(See Fig 5B). However, if caspase8 is inhibited, RIP1 can proceed to begin the 
necroptosis pathway. RIP1 is a protein kinase, and when active is highly 
phosphorylated. RIP1 phosphorylates and activates another vital mediator of 
necroptosis, RIP3 kinase, and together they form an amyloid-like structure 
dubbed ‘the necrosome’. The necrosome binds mixed lineage kinase domain-
like (MLKL), which is a substrate of RIP3. MLKL is then phosphorylated, and is 
recruited to the plasma membrane, where lysis can occur, finally resulting in the 
typical necroptotic rupture (summarised in Fig 7) [238, 269, 272, 276-278]. 
Although we now have a good idea of the signalling involved in necroptosis, the 
actual mechanisms of action are less clear. As MLKL signals to the 
mitochondria fission promoters, phosphoglycerate mutase family member 5 
(PGAM5) and dynamin-related protein 1 (Drp1), it is possible fragmentation of 
this organelle is involved. Other suggested mechanisms include further ROS 
production or ATP depletion [270, 279].  
Owing to the importance of the RIP1 and RIP3 proteins in necroptosis, they can 
be targeted in order to disrupt the process. The chemical agent necrostatin-1 
(Nec) locks RIP1 in its inactive form, therefore preventing the formation of the 
necrosome and averting necroptosis [280]. Similarly, genetic targeting of either 





















Figure 7: Regulation of mammalian necroptosis 
Necroptosis regulation follows a similar pathway to TNF mediated extrinsic apoptosis (Fig 
5B). Ligands bind to their corresponding death receptors at their extracellular ligand 
binding domains. Activated receptors then recruit the adaptor TRADD via their death 
domains, which in turn recruits a number of effectors, becoming Complex I. From here, 
FADD and Caspase-8 are incorporated to form Complex II. What happens next determines 
if cells are committed to apoptosis or necroptosis. If caspase-8 is activated, it degrades 
RIP1 and goes on to initiate apoptosis. However, if caspase-8 remains inactive, RIP1 
becomes phosphorylated, and goes on to phosphorylate RIP3. The now active RIP3 can in 
turn phosphorylate its substrate MLKL. MLKL then translocates to the cell membrane, 
leading to the characteristic cell swelling characteristic of necroptotic cell death. 
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1.8: The controversial history of autophagy in 
programmed cell death 
Despite typically being associated with pro-survival roles, autophagy has also 
long been referred to as a mechanism of PCD [20-22]. This concept is based on 
the observation that dying cells sometimes contain numerous autophagosomes 
in the cytoplasm. The prevailing theory is that these accumulations are the 
result of an over-activation of autophagy, which then causes excessive 
consumption and destruction of vital cellular components. The resulting damage 
would then prove lethal [23, 24]. However, this concept has courted controversy 
in the field. Critics have proposed that rather than a lethal influence, the 
autophagosome accumulations may actually represent a failing last-ditch 
rescue attempt for the cell. Therefore, these cases may represent cell death 
with autophagy, rather than cell death by autophagy. Indeed, this interpretation 
is more in line with the typical functions of autophagy in cell survival. Also, as 
the concept has been devised based on morphological observations, there has 
been very little mechanistic insight into how this autophagy cell death could 
occur [25-27]. To try and elucidate this issue, a few guidelines have been 
proposed that need to be fulfilled for an event to qualify as bona fide autophagy 
cell death. Most importantly, a true case of autophagy cell death should be 
dependent on the autophagy machinery. This means that conditions of 
autophagy depletion should be able to prevent such lethality to cells. In a similar 
vein, it has also been suggested that the cell death should be associated with 
an increase in overall autophagy activity. Finally, the other main avenues of 
PCD -apoptosis and necroptosis- should not be required for the cell death [237].  
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Although the concept of autophagy cell death is still a highly controversial issue, 
there have been several well supported cases [26, 283]. A number of these 
have come from apoptosis defective cell types [284-287]. For example, Bax/Bak 
double knockout (DKO) rat cells are resistant to apoptosis, and yet under 
certain stimuli still undergo cell death. However, this toxicity is alleviated with 
the addition of the chemical autophagy inhibitor 3-MA, or by targeting the 
autophagy machinery components Atg5 and Beclin1 for knockdown [24]. This 
suggests the possibility that autophagy may serve as a form of compensatory 
cell death when apoptosis is not feasible [288].  
Other strong support for autophagy cell death has come from studies into 
Drosophila development. The large scale clearance and degradation of cells in 
the development of salivary glands, midgut, and oocytes have all been 
associated with an induction of autophagy, which is perturbed in mutant animals 
defective for the process [289-291].  
Although the stimulation of autophagy following cellular stress is often protective, 
in some instances the increases in autophagosomes have been suggested to 
actually promote death. Despite autophagy usually affording a lifeline during 
starvation, the depletion of Atg1 in Dictyostelium discoideum has been linked to 
a reduction in death associated with nutrient withdrawal [292]. Similar effects 
have also been seen in mammals with rat hippocampal neural stem cells. After 
removing insulin, the cells succumb to death that is not associated with the 
activation of caspases, but does see an elevation in autophagy. Indeed, 
knocking down autophagy suppressed this death, whilst its stimulation with 
rapamycin exacerbated the lethality [293]. As well as starvation, a wealth of 
studies report a role of autophagy in the death of neurons during hypoxic or 
ischaemic stresses. In mice suffering such an injury, caspase depletion 
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provides limited rescue, whilst autophagy inhibition with 3-MA or knocking down 
Atg7 affords protection [294-296] (note that autophagy’s potential roles in 
neuron death are discussed at greater length in Button et al., (2015) in 
Appendix ii. 
Some interest has been directed as to whether increases in autophagy in 
tumours bears any influence on their death. As apoptosis is often defective in 
these malignancies, allowing them to persist, alternative mechanisms of eliciting 
cell death could be vital in the development of new treatment strategies. 
Interestingly, apoptosis deficient breast and lung cancers [286, 297], as well as 
myelomas [298] and glioblastomas [287] have all been found to be sensitive to 
cell death from autophagy overexpression. In addition, promoting autophagy 
can also exacerbate the effects of other treatments. Elevated autophagy can 
sensitise a variety of tumours to toxicity from certain chemotherapeutics [299-
301], radiotherapies [297, 302-305] and oncolytic viruses [306], with these 
benefits lost when the pathway is depleted. Paradoxically, the reverse 
observation has also been made. A number of studies have found that blocking 
autophagy flux with the lysosomal inhibitor CQ can augment standard 
chemotherapy and radiotherapy regimes, including glioma [199, 206], CML 
[197], lung [307] and colon cancers [204], amongst others. This conflicting 
scenario of autophagy in tumour death epitomises the confusion in the field, and 





1.9: Project aims 
Despite the long standing controversy, there appears to be sufficient evidence 
to implicate autophagy as a mechanism of PCD. However, the difficulty still lies 
in corroborating this phenomenon with the more commonly reported pro-
survival roles autophagy provides. It is thus important to clarify the contexts 
whereby autophagy changes between these two conflicting roles. The aim of 
this project is to attempt to shed some light on this paradoxical scenario, by first 
establishing a potential model of autophagy toxicity, and then testing if this can 
indeed induce cell death. 
The key feature that characterises all proposed cases of autophagy cell death is 
an abundance of autophagosomes. Whilst this has almost entirely been 
attributed to an increase in overall autophagy activity, we suggest an alternative 
explanation. Increases in autophagosome numbers can be the result of two 
differing scenarios: indeed, they can be representative of enhanced stimulation 
of the process (see Fig 8A), but also can instead be caused by a defect to their 
degradation at the lysosomes (see Fig 8B). Therefore, since promoted 
autophagy is largely seen as pro-survival, we deem the latter scenario of a 
failure in degradation to be the more likely to exert cellular toxicity. Under such 
conditions, autophagy cannot be completed, meaning many, if not all, of the 
benefits the process provides are lost. An interesting point to consider in this 
model is that several of the examples of autophagy cell death cited earlier noted 
a greater degree of toxicity could be attained by the use of autophagosome 
synthesis inducers. On the surface, these findings would seem to support the 
more ‘classical’ model of increased autophagy activity being culpable for the 
death, and not our suggested mechanism of degradation failure. However, we 
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argue that these potential events may not be mutually exclusive. It is possible 
that degradation dysfunction occurs first. Then, as autophagy cannot be 
completed, any further autophagosomes can be considered as futile, since they 
will not be processed and thus provide no benefit to the cell. Continued 
synthesis of futile autophagosomes may pose more strain on the cell, and 
ultimately result in its demise (a combination of two models in Fig 8). 
With these hypothetical models in mind, this project aimed to first establish a 
working model of autophagy based toxicity. If achieved, we also wanted to 























Figure 8: Potential mechanisms through which increased 
autophagosomes may lead to cell death 
Previous reports of autophagy cell death share the common feature of an increase in 
cytoplasmic autophagosomes. This raises two main possibilities, which differ drastically on 
the overall effect on the autophagy flux. A. In this scenario, an increase in autophagosome 
synthesis is culpable for the elevation in the vesicle numbers. It has been theorised this 
could prove lethal through the excessive capture and degradation of cellular components, 
such as vital organelles needed for continued survival. In effect, this could be seen as the 
cell ‘eating itself’. B. Unlike the previous scenario, in this instance autophagosome 
accumulations occur as the result of a defect to their lysosomal fusion/degradation. As 
autophagy activity is now inhibited, it is possible the loss of its numerous pro-survival roles 
result in cell death. For example, harmful toxins and aggregates that are usually cleared by 
the process will be able to persist. Additionally, an energy deficit may be elicited from 
cutting the amino acid lifeline autophagy provides. The combination of these factors could 
then culminate in cell death. 
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2: Materials & Methods 
2.1: Cell Lines, Antibodies and Reagents 
Antibodies  
RABBIT POLYCLONAL ANTIBODIES: anti-LC3 (1:10,000) (Novus Biologicals, 
NB100-2220); anti-phospho-70S6K (Thr389) (1:1,000) (Cell Signaling, 9205); 
anti-actin (1:2,000) (Sigma, A2066); anti-cleaved caspase 3 (1:1,000) (Cell 
Signaling, 9661); anti-caspase 3 (1:1,000) (Cell Signaling, 9662); anti-caspase 
9 (1:1,000) (Cell Signaling, 9504); anti-Atg5 (1:1,000) (Cell Signaling, 2630); 
anti-syntaxin17 (1:1,000) (MBL, PM076); anti-Atg16L1 (1: 1,000) (MBL, 
PM040Y); anti-Atg10 (1: 1,000) (Bio-Rad, AHP1890); anti-Beclin 1 (1:1,000) 
(Sigma, B6061); anti-Tomm20 (1:1,000) (Santa Cruz, FL-145).  
RABBIT MONOCLONAL ANTIBODIES: anti-Atg12 (1:500) (Cell Signaling, 
4180); anti-caspase 8 (1:1,000) (Cell Signaling, 4790); anti-RIP1 (1:1,000) (Cell 
Signaling, 3493); anti-LAMP1 (1:1,000) (Cell Signaling, 9091); anti-mTOR 7C10 
(1:500) (Cell Signaling, 2983); anti-Merlin (1:1,000) (Cell Signaling, 12888). 
MOUSE MONOCLONAL ANTIBODIES: anti-GAPDH (1:5,000) (Ambion, 
AM4300); anti-p62 (1:1,000) (BD, 610833); anti-tubulin (1:10,000) (Sigma, 
T9026); anti-HA (1:1,000) (Biolegend, 901501). 
GOAT POLYCLONAL ANTIBODIES: anti-cathepsin D (1:200) (Santa Cruz, sc-
6486). 
Reagents 
PI-103 (528100) was from EMD4Biosciences. Chloroquine (CQ) (C6628), 
staurosporine (STS) (S5921), 3-methyladenine (3-MA) (M9281), cycloheximide 
(CHX) (C4859), artesunate (ART) (A3731), necrostatin-1 (Nec) (N9037) and 
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rapamycin (Rap) (R0395) were purchased from Sigma. Bafilomycin A1 (Baf) 
(19-148) was from Millipore. NVP-BEZ-235 (10565) was purchased from 
Cayman Chemical. zVAD-fmk (zVAD) (627610) was a product of Merck. Human 
TNF-α was from Invitrogen (Sino Biological, 10602-HNAE-5). Trehalose (Tre) 
(VB2764) and Rilmenidine (Ril) (VB2706) were from Viva Bioscience.  
Cell Culture 
HeLa (cell line derived from human cervical cancer cells, used passage ~10-20), 
Bax/Bak wt and DKO MEFs (kindly provided by Dr Christoph Borner) (mouse 
embryonic fibroblasts, used passage ~10), RT4-D6P2T (Sigma) (cell line 
derived from rat schwann cells, used passage ~8-15), Atg16L1 WT and KO 
MEFs (kindly provided by Dr N. Mizushima) (mouse embryonic fibroblasts, used 
passage ~10), SK-N-SH (cell line derived from human bone marrow metastasis 
from neuroblastoma patient, used passage ~10-20), and HEK293 cells (cell line 
derived from human embryonic kidney cells, used passage ~10-20) were 
cultured with standard methods in Dulbecco’s Modified Eagle’s Media (DMEM) 
(D6046) supplemented with 10% Foetal Bovine Serum (FBS) (12133C, Sigma). 
mRFP-GFP-LC3 stably expressing HeLa cells were maintained in DMEM with 
10% FBS containing 100ug/ml Geneticin (G418) (A1720, Sigma) as the 
selection agent (used passage ~10-15). Atg5 tet off MEFs were maintained in 
DMEM with 10% FBS (used passage ~10). Expression of the Atg5 gene was 
knocked out following 48hr 10ng/µl Doxycycline treatment (BP2653-1, Fisher), 
therefore providing us an inducible system of preventing autophagosome 
synthesis. These cells have been characterised and explained more thoroughly 
previously [308]. HIB and TRA mesothelioma cells (cell lines derived from 
human malignant mesothelioma, used passage ~10) were cultured in RPMI-
1640 media (RO883) supplemented with 10% FBS.  
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Human primary schwannoma use required the ethical approval from patients for 
the usage of tumour samples. The methods for isolation were described by 
[309]. Briefly, schwannomas were removed surgically with patients under local 
anaesthesia, then pre-incubated for 1-7 days in incubation media (DMEM with 
10% FBS, 500 U/ml penicillin/streptomycin (pen/strep), 0.5µM forskolin (Tocris, 
1099), 2.5µg/ml amphotericin B) in 10% CO2. Tumours were then dissected into 
1mm long pieces and cultured in DMEM with 10% FCS containing 500 U/ml 
pen/strep, 160 U/ml collagenase type I (Sigma, CO130) and 1.25 U/ml dispase 
grade I (Roche, 04942086001). Tissue pieces were incubated in proteolytic 
enzymes for 24 hours, and then dissociated by trituration with a narrowed 
Pasteur pipette. The resulting cell suspension was resuspended in proliferation 
medium (DMEM with 10% FCS, 500 U/ml pen/strep, 0.5uM forskolin, 2.5µg/ml 
amphotericin B, 10nM b1-heregulin and 2.5µg/ml insulin (Sigma, 91077C). For 
experimental use, cells were seeded in 96 well plates (Greiner Bio-one, 
Stonehouse, UK), coated with 1mg/ml poly-L-lysine (Sigma, P8920) and 4µg/ml 
natural mouse laminin (Life Technologies, 23017015), at a density of 
approximately 3000 cells/well. The proliferation medium was changed every 3-4 
days (details in Button et al., (2014) in Appendix i). Primary cells were typically 
used at passage ~3-5. 
Transfection 
For both plasmid and siRNA transfection cells were split to 50-70% confluency. 
Lipofectamine 2000 (Invitrogen) was used for all transfections as directed by the 
manufacturer.  
Plasmid Transfection: Plasmids were generally transfected at amounts of 0.2-
0.4µg (refer to figure legends for specific experiments). Media was changed 
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following a 3 hour incubation, with cells typically collected/analysed between 48-
72 hours post transfection (see figure legends for specific experiments). 
Scramble plasmid was used as a negative control. 
Plasmid details: 
mRFP-GFP-LC3 (#21074), HA-Syn (40824) and GFP-Syn A53T (#40823) were 
from Addgene. GFP-HTT-21Q and GFP-HTT-72Q were described previously by 
[310]. 
siRNA Transfection: All siRNAs were transfected at a concentration of 50nM 
(unless otherwise stated). Media was changed following overnight incubation, 
and cells were typically collected/analysed between 48-72 hours post 
transfection (see figure legends for specific experiments). Non-targeting siRNA 
was used as a negative control. 
Human siRNA sequences (Invitrogen) 
Control: (Sense: 5'-CGUACGCGGAAUACUUCGA-3'); 
Caspase-3: (Sense: 5’-UGGAUUAUCCUGAGAUGGG-3’);  
Caspase-9: (Sense: 5’-GGUUCUCAGACCGGAAACA-3’);  
FRAP1 (mTOR): (Sense: 5’-GGGCAUGAAUCGGGAUGAU-3’); 
STX17: (Sense: 5’-GGAUGACCUAGUACUUCUG-3’) 
   (Sense: 5’-GACUGUUGGUGGAGCAUUU-3’); 
Vps33A: (Sense: 5’-GCAAGGCAAUAGUUUGGGA-3’); 
Atg10: (Sense: 5’-CCAUGGGACACUAUUACGC-3’); 
Beclin1 (Beclin1 siRNA #1): (Sense: 5’-GGUCUAAGACGUCCAACAA-3’). 
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Human siRNA sequences (Dharmacon):  
Caspase-8 siRNA (#J-003466-16); 
RIP1 (#J-004445-07);  
Atg16L1 (Smartpool). 
Human siRNA sequences (Cell Signaling Technologies): 
Beclin1 (Beclin1 siRNA #2): (Sense: 5’-GGUCUAAGACGUCCAACAA-3’). 
2.2: Cell Viability & Death Measures 
Cell Proliferation Assay 
Cell proliferation experiments were performed in 96 well plates, with cells 
maintained in 100µl media per well. Cells were typically plated at a density of 
4,000 cells per well. All proliferation measures were made using the BrdU Cell 
Proliferation Assay kit (Cell Signaling, 6813), following the manufacturer’s 
instructions. Cells were incubated with BrdU for 4hrs prior to analysis. 
Absorbance was read at 450nm using the TECAN GENios V4.62-07/01 
microplate reader (Tecan, Reading, UK) and XFLUOR4 Version 4.51 software 
(Tecan). 
Cell Viability Measurements 
All cell viability experiments were performed in 96 well plates, with cells 
maintained in 100µl media per well. Cells were typically plated at a density of 
4,000 cells per well for these experiments. 
MTT Assay: MTT was a product of Invitrogen (M6494). Briefly, 10µl of a 12mM 
MTT stock solution was added per well and incubated at 37oC for 4 hours to 
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allow for formazan crystal formation. The medium was then exchanged for 
100µl DMSO, and crystals were dissolved through pipetting before plate 
shaking for 10 min. Absorbance readings were taken at 562nm and corrected 
by subtracting a reference measurement at 650nm. All absorbance 
measurements were taken with the TECAN GENios V4.62-07/01 microplate 
reader (Tecan, Reading, UK) running XFLUOR4 Version V 4.51 software 
(Tecan). 
ATP Assay: ATP levels were measured as an indicator of viability using the Cell 
Titer-Glo Luminescent Cell Viability Assay kit (Promega, G7571) according to 
the manufacturer’s directions. Briefly, 100µl of Cell Titer-Glo reagent was added 
per well, and cells were then placed on a plate shaker for 5 min. Following a 
further incubation for 10 min at room temperature, luminescence was measured 
using the SPECTRA Max M5 plate reader. 
Cell Cytotoxicity Assay 
Cytotoxicity was measured using the CytoTox-Fluor Cytotoxicity Assay kit 
(Promega, G9621) as per the manufacturer’s instructions. Briely, 10µl of 
reagent was added to cell culture medium and then incubated at 37oC for 3hrs. 
Plates were put on a shaker for 5 min at room temperature before fluorescence 
was measured at 485nmex/535nmem with the TECAN GENios V4.62-07/01 
microplate reader (Tecan, Reading, UK) running XFLUOR4 Version V 4.51 
software (Tecan). 
Flow Cytometry- Cell Death  
Adherent cells were detached with trypsin and washed twice with cold PBS, 
then resuspended in 1x binding buffer (10mM HEPES, pH 7.4; 140mM NaCl; 
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2.5mM CaCl2) at a density of 1x106 cells/ml. We transferred 100µl of cells to a 
FACS tube, added 5ul propidium iodide (Sigma, P4170) and incubated for 15 
min at room temperature. We added 200µl of 1x binding buffer into each tube 
and analysed by flow cytometry. Flow cytometry was performed using the 
Becton-Dickinson (BD) Accuri C6 flow cytometer with data analysed with the 
accompanying software.  
 
 
2.3: Protein Analysis 
Immunoblot 
Cells were harvested and then lysed using 1x laemmli buffer. Lysates were 
boiled at 100oC for ~10 mins and then briefly centrifuged at 13,000RPM. 
Samples were run through SDS-PAGE using 10-12% acrylamide gels. After 
gels had run, protein was transferred to PVDF membranes using semi-dry 
transfer (Trans-Blot SD Semi-Dry Transfer Cell, Bio-Rad) for ~80 min. Following 
protein transfer, membranes were blocked in 5% milk and then incubated with 
primary antibody at 4oC overnight. Membranes were washed 3 times with 
1xTBST (5 min per wash) and incubated with the appropriate horseradish 
peroxidase (HRP) conjugated secondary antibodies at room temperature for 30 
min. After a further 3x 5 min 1xTBST washes membranes were briefly 
incubated with Pierce ECL Western Blotting Substrate (Fisher, 32106) and then 
blots were developed.  
Subcellular Fractionation 
Cells were harvested and washed in 1x PBS, and then resuspended in 
fractionation buffer (10mM HEPES pH 7.9, 10mM KCl, 1.5mM MgCl2, 0.1mM 
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EGTA, 0.5mM DTT, 0.5mM PMSF and 10ug/ml proteinase inhibitor). The mix 
was passed through a 21-gauge needle 10 times, then incubated on ice for 45 
min. Some of the lysate was then collected (total fraction), with the remainder 
centrifuged (30 min, 16,000 x g, 4oC). The supernatant was collected (cytosolic 
fraction). The pellet (membrane fraction) was washed twice with fractionation 
buffer (7 min, 16,000 x g, 4oC), before running through SDS-PAGE. 
2.4: Immunocytochemisty & Microscopy 
Immunocytochemistry 
Cells on coverslips were rinsed with 1x PBS and fixed using 4% 
paraformaldehyde for 10 min. Following another three 1x PBS washes, fixed 
cells were permeabilised with 1x PBS containing 0.5% Triton for 10 min. Cells 
were blocked in blocking buffer (consisting of 1% BSA and 1% heat inactivated 
goat serum in 1x PBS) for 30 min at room temperature, then incubated with 
primary antibodies overnight at 4oC. This was followed by three 10 min 1x PBS 
washes, then incubation with the corresponding secondary antibody for 30 min 
(room temp). After a further three 10 min 1x PBS washes, slides were mounted 
in glycerol containing DAPI (3µg/ml). 
Confocal Microscopy 
All imaging was performed on a Leica TCS SP8 confocal microscope. 
mRFP-GFP-LC3 quantification 
Autophagy flux assessment was measured using HeLa cells stably expressing 
mRFP-GFP-LC3 that were fixed using the usual protocol. Numbers of green 
and red vesicles were scored. Green vesicles are considered to represent 
autophagosomes, whilst the red vesicles represent both autophagosomes and 
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autolysosomes. Subtracting the total green vesicles from the red therefore gives 
a measure of autolysosomes. 
Acridine Orange Staining 
Following the desired drug treatment incubation, cells were stained with 
2.5µg/µl acridine orange (Fisher, A1301) for 15 min at 37oC. Cells were rinsed 
twice with 1x PBS. Live confocal cell imaging was performed on a Leica 
TCSSP8 with a 1.4nm 63x objective. The argon laser at 488nm was used for 
excitation, and emission collected simultaneously at both 505-570nm (to show 
non-acidic cell regions) and 615-754nm (for acidic regions).  
LysoSensor Green Staining 
Following the desired drug treatment incubation, cells were stained with 1µM 
LysoSensor Green DND-189 (Fisher, L7535) for 30 min at 37oC. Cell media 
was exchanged and then live confocal cell imaging was performed using an 
excitation wavelength of 488nm. 
2.5: Polymerase Chain Reaction (PCR) 
qRT-PCR analysis 
RNA was isolated with the TRIzol reagent as directed (Invitrogen). For qPCR, 
1µg of the isolated RNA was reverse transcribed (Applied Biosystems) using 
cycles of 25oC (10 min), 37oC (120 min) and 85oC (5 min). Resulting cDNA 
templates were used in qPCR with LightCycler 480 DNA SYBR Green I Master 
kit (Roche) in LightCycler 480 II system (Roche). All primers were from Sigma 
and used at 0.5µM concentration. Actin was used as a control in order to 
normalise the data.  
 
